Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $41.20 Consensus Target Price from Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the thirteen research firms that are currently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $41.20.

Several research firms have commented on KYMR. Wolfe Research began coverage on shares of Kymera Therapeutics in a research note on Thursday, February 15th. They issued a "peer perform" rating for the company. Bank of America lowered shares of Kymera Therapeutics from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $45.00 to $30.00 in a research note on Wednesday, January 3rd. JPMorgan Chase & Co. increased their price objective on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the company an "overweight" rating in a research note on Friday, February 23rd. Truist Financial increased their target price on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the company a "buy" rating in a research report on Friday, March 1st. Finally, Stifel Nicolaus increased their target price on shares of Kymera Therapeutics from $35.00 to $55.00 and gave the company a "buy" rating in a research report on Friday, February 23rd.

Kymera Therapeutics Price Performance

Shares of KYMR stock traded up $1.36 on Tuesday, reaching $35.71. 437,028 shares of the company were exchanged, compared to its average volume of 737,448. The company has a market cap of $2.18 billion, a price-to-earnings ratio of -14.48 and a beta of 2.27. The company has a 50-day moving average of $39.12 and a 200-day moving average of $28.18. Kymera Therapeutics has a one year low of $9.60 and a one year high of $45.31.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.19. The firm had revenue of $47.90 million during the quarter, compared to analyst estimates of $41.94 million. Kymera Therapeutics had a negative net margin of 187.00% and a negative return on equity of 34.83%. The company's revenue for the quarter was up 197.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.60) EPS. As a group, sell-side analysts predict that Kymera Therapeutics will post -3.13 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $42.85, for a total value of $1,812,640.70. Following the completion of the transaction, the insider now directly owns 4,925,812 shares of the company's stock, valued at approximately $211,071,044.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Kymera Therapeutics news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the firm's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $42.85, for a total value of $1,812,640.70. Following the completion of the transaction, the insider now directly owns 4,925,812 shares of the company's stock, valued at approximately $211,071,044.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jared Gollob sold 46,137 shares of the firm's stock in a transaction on Friday, February 9th. The shares were sold at an average price of $35.50, for a total transaction of $1,637,863.50. Following the completion of the transaction, the insider now directly owns 74,709 shares of the company's stock, valued at $2,652,169.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 474,051 shares of company stock valued at $19,624,211. Company insiders own 16.67% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its holdings in Kymera Therapeutics by 5.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,335,712 shares of the company's stock valued at $135,848,000 after purchasing an additional 278,287 shares during the period. BVF Inc. IL raised its position in Kymera Therapeutics by 8.9% in the 4th quarter. BVF Inc. IL now owns 5,161,801 shares of the company's stock worth $131,419,000 after purchasing an additional 422,797 shares during the period. Vanguard Group Inc. raised its position in Kymera Therapeutics by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 3,997,564 shares of the company's stock worth $101,778,000 after purchasing an additional 72,351 shares during the period. Rock Springs Capital Management LP increased its position in shares of Kymera Therapeutics by 1.1% in the third quarter. Rock Springs Capital Management LP now owns 1,504,351 shares of the company's stock valued at $20,910,000 after acquiring an additional 16,800 shares during the period. Finally, FMR LLC increased its position in shares of Kymera Therapeutics by 3.9% in the third quarter. FMR LLC now owns 870,547 shares of the company's stock valued at $12,101,000 after acquiring an additional 32,335 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.